keyword
MENU ▼
Read by QxMD icon Read
search

Apremilast

keyword
https://www.readbyqxmd.com/read/27878061/oral-apremilast-for-the-treatment-of-plaque-psoriasis
#1
REVIEW
James Q Del Rosso, Leon Kircik
This article provides an update on the use of oral apremilast, a phosphodiesterase-4 (PDE4) inhibitor, for the treatment of plaque psoriasis. Emphasis is placed on safety evaluations, although efficacy considerations are also addressed. Both two-year and three -year data analyses support the favorable safety profile reported in pivotal trials with this agent. Although effective in many study subjects despite baseline characteristics, higher response rates were noted in those with a baseline psoriasis area and severity index (PASI) score <20 and in subjects not previously treated with systemic therapy for psoriasis...
September 2016: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/27870479/impact-of-renal-impairment-on-the-pharmacokinetics-of-apremilast-and-metabolite-m12
#2
Yong Liu, Simon Zhou, Mahmoud Assaf, Jim Nissel, Maria Palmisano
The pharmacokinetics of apremilast and its major metabolite M12 were evaluated in subjects with varying degrees of renal impairment. Men and women with renal impairment (estimated glomerular filtration rate, 60-89 mL/min [mild, n = 8], 30-59 mL/min [moderate, n = 8], or <30 mL/min [severe, n = 8]) or demographically healthy matched (control) subjects (n = 24) received a single oral dose of apremilast 30 mg. Plasma apremilast and metabolite M12 concentrations were determined, and pharmacokinetic parameters were calculated from samples obtained predose and up to 72 hours postdose...
November 2016: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27869356/apremilast-an-oral-phosphodiesterase-4-pde4-inhibitor-a-novel-treatment-option-for-nurse-practitioners-treating-patients-with-psoriatic-disease
#3
Melodie Young, Heather L Roebuck
BACKGROUND AND PURPOSE: Apremilast is an oral nonbiologic medication approved for the treatment of adult patients with active psoriatic arthritis and for patients with moderate to severe plaque psoriasis. This article summarizes the efficacy and safety of apremilast and provides characterization of the novel medication with clinical perspectives to successfully incorporate this therapy into practice for appropriate patients. DATA SOURCES: A review and synthesis of the results from the ESTEEM (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis) phase 3 clinical studies evaluating the efficacy, safety, and tolerability of apremilast for the treatment of moderate to severe plaque psoriasis was conducted...
December 2016: Journal of the American Association of Nurse Practitioners
https://www.readbyqxmd.com/read/27856658/new-targets-in-psoriatic-arthritis
#4
REVIEW
Juergen Braun
PsA is an immune-mediated chronic inflammatory disease that affects both skin and joints; it is a heterogeneous disease characterized by synovitis, enthesitis, dactylitis and spondylitis. The impact on patients and the burden of disease are substantial. For assessment of the disease, patient-reported outcomes are increasingly important. Conventional therapy consists of NSAIDs, local and systemic CSs, and synthetic and biological DMARDs. While MTX, LEF, SSZ and CYC are the synthetic drugs mainly used, TNF-α blocking agents have represented the majority of biologics used in the last decade (infliximab, etanercept, adalimumab, certolizumab and golimumab)...
December 2016: Rheumatology
https://www.readbyqxmd.com/read/27846946/appearance-of-lentigines-in-psoriasis-patients-treated-with-apremilast
#5
Alicia Sfecci, Abdallah Khemis, Jean-Philippe Lacour, Henri Montaudié, Thierry Passeron
No abstract text is available yet for this article.
December 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27846617/real-world-experience-with-apremilast-in-treating-psoriasis
#6
Julia N Mayba, Melinda J Gooderham
BACKGROUND: Clinical trial data have shown apremilast, an oral phosphodiesterase-4 inhibitor, to be efficacious and safe for the treatment of psoriasis. However, little real-world experience using apremilast in the community setting has been documented. OBJECTIVES: Many patients with psoriasis are often unresponsive to various treatment modalities, including topical, systemic, and biologic medications. The aim of this chart review was to assess the overall patient experience while using apremilast to treat psoriasis...
October 21, 2016: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/27846018/clearance-of-erythroderma-in-a-patient-on-apremilast-and-positive-patch-test-reactions-while-on-treatment
#7
Cameron E West, Joseph F Fowler
No abstract text is available yet for this article.
November 2016: Dermatitis
https://www.readbyqxmd.com/read/27836567/management-of-psoriatic-arthritis-early-diagnosis-monitoring-of-disease-severity-and-cutting-edge-therapies
#8
REVIEW
Siba P Raychaudhuri, Reason Wilken, Andrea C Sukhov, Smriti K Raychaudhuri, Emanual Maverakis
Psoriatic arthritis (PsA) is a heterogeneous disease that can involve a variety of distinct anatomical sites including a patient's peripheral and axial joints, entheses, skin and nails. Appropriate management of PsA requires early diagnosis, monitoring of disease activity, and utilization of cutting edge therapies. To accomplish the former there are a variety of PsA-specific tools available to screen, diagnose, and assess patients. This review will outline the recently developed PsA screening tools, including the Toronto Psoriatic Arthritis Screening Questionnaire (TOPAS), the Psoriasis Epidemiology Screening Tool (PEST), the Psoriatic Arthritis Screening and Evaluation (PASE), and the Psoriasis and Arthritis Screening Questionnaire (PASQ)...
November 8, 2016: Journal of Autoimmunity
https://www.readbyqxmd.com/read/27829672/management-of-psoriatic-arthritis-in-2016-a-comparison-of-eular-and-grappa-recommendations
#9
REVIEW
Laure Gossec, Laura C Coates, Maarten de Wit, Arthur Kavanaugh, Sofia Ramiro, Philip J Mease, Christopher T Ritchlin, Désirée van der Heijde, Josef S Smolen
Psoriatic arthritis (PsA) is a heterogeneous, potentially severe disease. Many therapeutic agents are now available for PsA, but treatment decisions are not always straightforward. To assist in this decision making, two sets of recommendations for the management of PsA were published in 2016 by international organizations - the European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). In both sets of recommendations, the heterogeneity of PsA is recognized and the place of various drugs in the therapeutic armamentarium is discussed...
November 10, 2016: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/27826996/treatment-of-psoriatic-arthritis-with-traditional-dmard-s-and-novel-therapies-approaches-and-recommendations
#10
Ajesh B Maharaj, Vinod Chandran
Recent advances in the therapeutics of psoriatic arthritis (PsA) have provided more options to clinicians managing PsA. The purpose of this review is to update the reader on treatment options for PsA using conventional synthetic disease modifying agents (csDMARDs) and novel therapies including tumour necrosis factor alpha inhibitors, interleukin 12/23 inhibitor (ustekinumab), the interleukin 17 antagonists including secukinumab, brodalumab, ixekizumab, and the phosphodiesterase-4 inhibitor, apremilast. Areas covered: We reviewed published articles on the treatment of PsA...
November 18, 2016: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/27785949/apremilast-reversed-carfilzomib-induced-cardiotoxicity-through-inhibition-of-oxidative-stress-nf-%C3%AE%C2%BAb-and-mapk-signaling-in-rats
#11
Faisal Imam, Naif O Al-Harbi, Mohammad Matar Al-Harbi, Mushtaq Ahmad Ansari, Mashal M Almutairi, Musaad Alshammari, Talal Saad Almukhlafi, Mohd Nazam Ansari, Khaldoon Aljerian, Sheikh Fayaz Ahmad
Carfilzomib (CFZ), is a potent, selective second generation proteasome inhibitor, used for the treatment of multiple myeloma. The aim of the present study was to investigate the possible protective effect of apremilast (AP) on the CFZ -induced cardiotoxicity. Rats were randomly divided into four groups: Group 1, served as the control group, received normal saline. Group 2, served as the toxic group, received CFZ (4 mg/kg, intraperitoneally [i.p.]). Groups 3 and 4, served as treatment groups, and received CFZ with concomitant oral administration of AP in doses of 10 and 20 mg/kg/day, respectively...
October 27, 2016: Toxicology Mechanisms and Methods
https://www.readbyqxmd.com/read/27768242/the-efficacy-and-safety-of-apremilast-etanercept-and-placebo-in-patients-with-moderate-to-severe-plaque-psoriasis-52-week-results-from-a-phase-3b-randomized-placebo-controlled-trial-liberate
#12
K Reich, M Gooderham, L Green, A Bewley, Z Zhang, I Khanskaya, R M Day, J Goncalves, K Shah, V Piguet, J Soung
BACKGROUND: Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate to severe psoriasis. OBJECTIVE: Evaluate efficacy and safety of apremilast vs. placebo in biologic-naive patients with moderate to severe plaque psoriasis and safety of switching from etanercept to apremilast in a phase IIIb, randomized, double-blind, placebo-controlled study (NCT01690299). METHODS: 250 patients were randomized to placebo (n=84), apremilast 30 mg BID (n=83) or etanercept 50 mg QW (n=83) through Week 16; thereafter, all patients continued or switched to apremilast through Week 104...
October 21, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27747584/economic-evaluation-of-timely-versus-delayed-use-of-tumor-necrosis-factor-inhibitors-for-treatment-of-psoriatic-arthritis-in-the-us
#13
Vibeke Strand, Elaine Husni, Jenny Griffith, Zheng-Yi Zhou, James Signorovitch, Arijit Ganguli
INTRODUCTION: The present study aimed to evaluate clinical outcomes and costs associated with timely versus delayed use of tumor necrosis factor inhibitors (TNFis) among patients with moderately to severely active psoriatic arthritis (PsA) with and without moderate/severe psoriasis (Ps) from a US payer's perspective. METHODS: An economic model evaluated PsA patients initially treated with a TNFi (timely TNFi use) or apremilast (delayed TNFi use). Patients without joint (American College of Rheumatology 20%, [ACR20]) improvement either switched TNFis or initiated one...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27721755/apremilast-is-effective-in-lichen-planus-mucosae-associated-stenotic-esophagitis
#14
Jürg Hafner, Christoph Gubler, Karin Kaufmann, Stephan Nobbe, Alexander A Navarini, Lars E French
A 74-year-old woman with extensive lichen planus mucosae (LPM) developed stenotic esophagitis that was refractory to intravenous glucocorticosteroids. Esophageal dilatations to 14 mm width were repeatedly performed without any lasting effect. After introducing oral apremilast, she experienced complete clinical remission within the first 4 weeks of treatment. Control esophagoscopy confirmed a marked recovery of the esophageal mucosa with no recurrence of the former stenosis. Our observation is in line with the case series of Paul et al...
May 2016: Case Reports in Dermatology
https://www.readbyqxmd.com/read/27672415/new-oral-therapies-for-psoriasis-a-comprehensive-review
#15
REVIEW
Gary Goldenberg, Julien Lanoue, Joanna Dong
Conventional oral therapies for psoriasis, including methotrexate, cyclosporine, and acitretin, have generally unfavorable safety profiles and are not ideal for long-standing use. Thus, new oral therapies are necessary for patients with more moderate disease, patients who prefer oral treatments to injectable biologies, and patients who failed conventional therapies. The authors review here the clinical and safety evidence of phosphodiesterase 4 inhibitor, apremilast, janus kinase inhibitors, including tofacitinib, and fumarie acid esters as additional options in oral psoriasis therapy...
August 2016: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/27608793/-not-available
#16
F M Perrotta, E Lubrano
Psoriatic arthritis (PsA) is a chronic inflammatory disease that possibly leads to structural damage and to a reduction of joint function and poor quality of life. Treatment of PsA has changed since its introduction of anti- TNF drugs, which have shown to reduce the symptoms and signs of the disease and slow the radiographic progression. However, recently, the discovery of new pathogenic mechanisms have made possible the development of new molecules that target pro-inflammatory cytokines involved in skin, joint and entheseal inflammation...
2016: Reumatismo
https://www.readbyqxmd.com/read/27602700/new-therapies-for-psoriasis
#17
Bruce E Strober
Among the newer medications for treating psoriasis are the interleukin-17A inhibitor secukinumab and the phosphodiesterase 4 inhibitor apremilast. Secukinumab offers a level of efficacy greater than that of the tumor necrosis factor-α inhibitor adalimumab. Apremilast is associated with lower levels of efficacy than the biologic therapies for psoriasis. Apremilast may cause diarrhea and nausea and is associated with weight loss and rare instances of depression. Semin Cutan Med Surg 35(supp4):S71-S73.
June 2016: Seminars in Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/27578078/itch-in-psoriasis-management
#18
Jacek C Szepietowski, Adam Reich
Psoriasis is a common chronic inflammatory skin disease observed in about 1-3% of the general population. About 60-90% of patients with psoriasis suffer from itching. Interestingly, in the past itch was not considered as an important symptom of psoriasis. Despite the high frequency of itch in psoriasis, the pathogenesis of this symptom is still not fully elucidated. Although most studies indicate neurogenic inflammation and the role of neuropeptides, other mediators may be important as well. The majority of psoriatic patients consider itch as the most bothersome symptom of the disease as it significantly alters daily functioning and psychosocial well-being...
2016: Current Problems in Dermatology
https://www.readbyqxmd.com/read/27568485/development-of-an-extended-release-formulation-for-apremilast-and-a-level-a-in-vitro-in-vivo-correlation-study-in-beagle-dogs
#19
Meiqiong Tang, Ping Hu, Shigui Huang, Qiang Zheng, Hao Yu, Yun He
The primary objective of the present study was to develop extended-release matrix formulations of apremilast for the oral delivery and to study their in vitro and in vivo correlation. Five extended-release formulations containing hydroxypropylmethylcellulose (HPMC) as the retarding excipient with different release rate of apremilast were prepared. Dissolution tests of all the formulated tablets were performed in water, pH 4.0 and pH 6.8 buffer solutions. The in vitro release kinetics was studied and supported by Korsmeyer-Peppas's equation as it presented highest values of correlation coefficients (r(2) up to 0...
August 26, 2016: Chemical & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/27538241/apremilast-an-oral-phosphodiesterase-4-inhibitor-improves-patient-reported-outcomes-in-the-treatment-of-moderate-to-severe-psoriasis-results-of-two-phase-iii-randomized-controlled-trials
#20
D Thaçi, A Kimball, P Foley, Y Poulin, E Levi, R Chen, S R Feldman
BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, has an acceptable safety profile and is effective for treatment of plaque psoriasis and psoriatic arthritis. OBJECTIVES: To evaluate the impact of apremilast on health-related quality of life (HRQOL), general functioning and mental health using patient-reported outcome (PRO) assessments among patients with moderate to severe plaque psoriasis in the ESTEEM 1 and 2 trials. METHODS: A total of 1255 patients were randomized (2 : 1) to apremilast 30 mg BID or placebo for 16 weeks; all received apremilast through Week 32...
August 18, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
64665
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"